FIELD: medicine.
SUBSTANCE: invention relates to oncology, and can be used for treating castration-resistant prostate cancer. For this purpose, simultaneously with a combination of docetaxel 75 mg/m2 of body surface once every 3 weeks + enzalutamide 160 mg a day + prednisolone 10 mg a day is prescribed orally twice day 50–200 mg after meals. Duration of therapeutic course is 3 weeks.
EFFECT: method enables higher clinical effectiveness and safety ensured by the additive effect of the combination.
1 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF CASTRATION-RESISTANT PROSTATE CANCER TREATMENT | 2017 |
|
RU2696287C2 |
| METHOD OF TREATING CASTRATION-RESISTANT PROSTATE CANCER | 2017 |
|
RU2673816C1 |
| METHOD OF CASTRATION-RESISTANT PROSTATE CANCER TREATMENT | 2017 |
|
RU2700573C2 |
| METHOD OF CASTRATION-RESISTANT PROSTATE CANCER TREATMENT | 2017 |
|
RU2694373C2 |
| METHOD OF CASTRATION-RESISTANT PROSTATE CANCER TREATMENT | 2017 |
|
RU2694259C2 |
| MEANS OF TREATMENT AND RELAPSE PREVENTION OF PROSTATE CANCER | 2006 |
|
RU2325160C1 |
| METHOD FOR THE TREATMENT OF PRIMARY METASTATIC PROSTATE CANCER | 2022 |
|
RU2796395C1 |
| METHOD OF TREATING PATIENTS WITH METASTASES IN LYMPH NODES AND OLIGOMETASTATIC DISEASE IN BONES OF SKELETON IN PROSTATE CANCER | 2018 |
|
RU2695348C2 |
| CANCER TREATMENT METHODS | 2019 |
|
RU2811406C2 |
| MEANS AND METHOD OF CONDITIONS TREATMENT IMPLYING ANDROGEN ACTION DECREASE IS CONSIDERED TO BE FAVOURABLE, AND METHOD OF ANDROGEN-DEPENDENT TISSUE SENSITIVITY ITENSIFYING USING 9-OXOACRIDINE-10-ACETIC ACID | 2006 |
|
RU2328285C2 |
